Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 23, 2026, details a material definitive agreement entered into by Citius Pharmaceuticals, Inc. The company, incorporated in Nevada and trading on the Nasdaq Capital Market, announced the closing of a registered direct offering and a concurrent private placement on April 24, 2026.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $5.0 million.
- Net Proceeds: Approximately $4.5 million after deducting placement agent fees and offering expenses.
- Securities Issued:
- 4,730,457 shares of common stock at $0.985 per share.
- Pre-funded warrants to purchase up to 345,686 shares at $0.9849 per share.
- Common warrants to purchase up to 5,076,143 shares at an exercise price of $0.86 per share.
- Placement Agent Fees: 7.0% of gross proceeds, plus reimbursement for legal fees (up to $50,000), non-accountable expenses ($35,000), and a clearing fee ($15,950).
- Placement Agent Warrants: 355,330 warrants issued to H.C. Wainwright and Co., LLC with an exercise price of $1.2313 per share.
Material Changes and Use of Proceeds
The filing represents a significant capital raise event. The company anticipates using the net proceeds to support the ongoing commercialization of its product LYMPHIR™, including milestone and regulatory payments, development initiatives for other product candidates, and general corporate purposes. The filing does not provide comparative financial metrics (revenue, profit, cash flow) as this is a transactional report rather than a periodic financial statement.
Outlook, Risks, and Unusual Items
- Lock-Up Period: The Company agreed to a 45-day lock-up period following the closing, during which it cannot issue or announce the issuance of additional common stock or convertible securities, subject to certain exceptions.
- Beneficial Ownership Limitation: Warrant holders are restricted from exercising if it would result in beneficial ownership exceeding 4.99% (or 9.99% at election) of outstanding shares, unless 61 days' prior notice is given.
- Warrant Terms: Common Warrants are exercisable immediately with a five-year term. If no effective registration statement exists for resale, holders may elect a cashless exercise. Unexercised warrants will be automatically exercised via cashless exercise upon expiration.
Key Facts for Investor Verification
- Verify the actual closing date and final net proceeds received, as the filing states proceeds are "expected" to be approximately $4.5 million.
- Confirm the dilution impact of the 5,076,143 Common Warrants and 355,330 Placement Agent Warrants on existing shareholders.
- Review the specific milestones and regulatory payment schedules for LYMPHIR™ to assess the sufficiency of the $4.5 million net proceeds.
- Monitor the 45-day lock-up period expiration to evaluate potential for near-term additional equity issuance.